Location History:
- Moutain View, CA (US) (2017)
- Mountain View, CA (US) (2017 - 2019)
- Los Gatos, CA (US) (2020)
Company Filing History:
Years Active: 2017-2020
Title: The Innovative Contributions of Geoff McKinley
Introduction
Geoff McKinley is a prominent inventor based in Mountain View, CA (US). He has made significant contributions to the field of pharmaceuticals, particularly through his innovative work on ergoline compounds. With a total of 10 patents to his name, McKinley continues to push the boundaries of medical science.
Latest Patents
One of McKinley's latest patents focuses on ergoline compounds and their various uses. This patent outlines pharmaceutical compositions that can be utilized for the treatment, prevention, or amelioration of several medical disorders, including migraines. The patent also describes methods for agonizing specific receptors, such as the 5-HT receptors, while avoiding the 5-HT receptor itself. Additionally, it details methods for antagonizing the 5-HT adrenergic alpha receptors and the D2 and D3 receptors, showcasing the versatility and potential of these compounds in medical applications.
Career Highlights
Geoff McKinley is currently associated with Xoc Pharmaceuticals, Inc., where he continues to develop innovative solutions in the pharmaceutical industry. His work has not only advanced the understanding of ergoline compounds but has also contributed to the development of new treatment methodologies for various medical conditions.
Collaborations
Throughout his career, McKinley has collaborated with notable colleagues, including Thomas A. Armer and Scott Borland. These partnerships have fostered a collaborative environment that enhances the innovation process and leads to groundbreaking discoveries.
Conclusion
Geoff McKinley's contributions to the field of pharmaceuticals through his innovative work on ergoline compounds exemplify the impact of dedicated inventors in advancing medical science. His ongoing research and collaborations continue to pave the way for new treatment options and improved patient outcomes.